*Carcinoma Transitional Cell Case-Control Studies Epidemiologic Studies Female Folic Acid Humans Male Prospective Studies Risk Factors *Urinary Bladder Neoplasms/epidemiology/etiology/prevention & control

Administration Intravesical *Carcinoma Transitional Cell/pathology Epirubicin/therapeutic use Female Humans Male Mitomycin/therapeutic use Neoplasm Recurrence Local Randomized Controlled Trials as Topic *Urinary Bladder Neoplasms/pathology Intravesical Chemotherapy Non-muscle Invasive Bladder Cancer Turb

Apoptosis B7-H1 Antigen/genetics/metabolism *Carcinoma Transitional Cell/pathology Cystectomy Humans Immune Checkpoint Inhibitors Ligands Lymph Node Excision Neoplasm Recurrence Local/pathology Prognosis Programmed Cell Death 1 Receptor Urinary Bladder *Urinary Bladder Neoplasms/pathology bladder urothelial carcinoma meta-analysis prognostic value programmed cell death ligand-1 radical cystectomy commercial or financial relationships that could be construed as a potential conflict of interest.

Administration Intravesical *Carcinoma Transitional Cell/pathology Humans Male Neoplasm Invasiveness/pathology Neoplasm Recurrence Local/pathology Neoplasm Staging *Urinary Bladder Neoplasms/drug therapy/therapy

Humans *Carcinoma Transitional Cell/diagnosis/therapy *Urinary Bladder Neoplasms Systematic Reviews as Topic Kidney Oregon *Ureteral Neoplasms/diagnosis/therapy Utuc renal pelvis cancer upper tract urothelial cancer ureteral cancer urothelial cancer

*Carcinoma Transitional Cell/pathology Female Humans Male Neoplasm Invasiveness Nephroureterectomy Sweden *Urinary Bladder Neoplasms/pathology Swedish national guidelines Urothelial carcinoma non-muscle invasive bladder cancer upper tract urothelial carcinoma

Antineoplastic Combined Chemotherapy Protocols/therapeutic use *Carcinoma Transitional Cell/pathology Cisplatin/therapeutic use Cystectomy Humans Muscles/pathology Neoadjuvant Therapy Neoplasm Invasiveness *Urinary Bladder Neoplasms/pathology Bladder cancer Muscle-invasive Urothelial from MSD and BMS and Speaker and Other from AstraZecena. BPV reports Advisory Board Speaker and Other from Astellas Roche BMS and Merk-Pfizer Advisory Board and Other from Ipsen Advisory Board and Speaker from EUSA and MSD and Advisory Board from Sanofi. IPF report Advisory Board Speaker and Other from Pfizer Speaker and Other from Ipsen and Roche Advisory Board from EUSA and BMS and Speaker from Novartis and MSD. OFC reports Advisory Board and Speaker from Ipsen and Astellas Advisory Board from BMS and Pfizer-Merck and Speaker from AstraZeneca. AGA has received research funding from Astellas travel grants from Astellas Jansen Sanofi BMS Roche Pfizer and Ipsen and honoraria for speaker engagements advisory boards and continuous medical education from Janssen Astellas Sanofi Bayer Roche Ipsen BMS MSD Pfizer Eusa Pharma Eisai and AstraZeneca. JAA reports honoraria from Astellas Pfizer and BMS conulting or advisory role from Pfizer Astellas Janssen-Cilag MSD Oncology BMS Merck AstraZeneca Bayer and Eisai and Research Funding from BMS. RMB SVE CCD and MDS have nothing to disclose.

*Carcinoma Transitional Cell/drug therapy/pathology Cisplatin Female Humans Male *Urinary Bladder Neoplasms/drug therapy/pathology *Urology *Bladder cancer *European Association of Urology *Guidelines *Immunotherapy *Metastatic *Systemic therapy *Urothelial carcinoma

*Carcinoma Transitional Cell/pathology/surgery Combined Modality Therapy Consensus Humans Neoplasm Invasiveness/pathology Quality of Life Urinary Bladder/pathology/surgery *Urinary Bladder Neoplasms/drug therapy/surgery Bladder neoplasms Bladder preservation Expert consensus Multi-disciplinary treatment

*Carcinoma Transitional Cell/pathology Humans Prognosis Retrospective Studies *Ureteral Neoplasms *Urinary Bladder Neoplasms *Urologic Neoplasms/pathology Carcinoma Transitional Cell Pathology

Humans *Carcinoma Transitional Cell/secondary *Urinary Bladder Neoplasms/pathology

Humans Biomarkers Tumor *Carcinoma in Situ/diagnosis *Carcinoma Transitional Cell/pathology Hyaluronan Receptors/metabolism Keratin-20/analysis/metabolism Ki-67 Antigen/metabolism Tumor Suppressor Protein p53/analysis/metabolism Urinary Bladder *Urinary Bladder Neoplasms/pathology Urothelium/chemistry/metabolism/pathology Bladder carcinoma Carcinoma in situ Carcinoma vesical Displasia Dysplasia Immunomarkes Inmunomarcadores

Antineoplastic Combined Chemotherapy Protocols/adverse effects Bayes Theorem *Carcinoma Transitional Cell/drug therapy/surgery Humans Network Meta-Analysis *Urinary Bladder Neoplasms/drug therapy/surgery Ici Pd-1 Pd-l1 adjuvant therapy chemotherapy urothelial carcinoma

*Carcinoma Transitional Cell/pathology/radiotherapy Humans *Kidney Neoplasms Kidney Pelvis/pathology Prognosis *Ureteral Neoplasms/pathology *Urinary Bladder Neoplasms Adjuvant radiotherapy Prognostic Radiotherapy Survival Upper urinary tract urothelial carcinoma

*Carcinoma Transitional Cell Cystectomy/adverse effects Humans Morbidity Smoking/adverse effects *Urinary Bladder Neoplasms/epidemiology/surgery Complication Infection Outcome Perioperative mortality Radical cystectomy Smoking exposure Urothelial bladder cancer

*Carcinoma Renal Cell/surgery *Carcinoma Transitional Cell Humans *Kidney Neoplasms/surgery Nutritional Status Prognosis Retrospective Studies *Urinary Bladder Neoplasms *Urinary Tract

*Carcinoma Transitional Cell/surgery Cystectomy/adverse effects Humans Neoplasm Recurrence Local *Urinary Bladder Neoplasms/surgery

Administration Intravesical BCG Vaccine/therapeutic use *Carcinoma in Situ/diagnosis/therapy Female Humans Male Neoplasm Invasiveness *Urinary Bladder Neoplasms/diagnosis/pathology/therapy *Urology *BCG unresponsive *Bacillus Calmette-Guerin (BCG) *Bladder cancer *Cystoscopy *Diagnosis *European Association of Urology (EAU) *Follow-up *Guidelines *Intravesical chemotherapy *Prognosis *Radical cystectomy *Transurethral resection (TUR) *Urothelial carcinoma

5-alpha Reductase Inhibitors/therapeutic use Androgen Antagonists/therapeutic use Androgens/therapeutic use *Carcinoma in Situ Humans Male *Prostatic Neoplasms/pathology *Urinary Bladder Neoplasms/pathology *Androgen suppression therapy *Androgens *Bladder cancer *Incidence *Recurrence *Systematic review

*Carcinoma Transitional Cell Evidence-Based Medicine Humans *Radiology Societies Medical United States *Urinary Bladder Neoplasms/diagnostic imaging Auc Appropriate Use Criteria Appropriateness Criteria Bladder cancer Muscle invasive bladder cancer Nonmuscle invasive bladder cancer Surveillance Transitional cell carcinoma Urothelial cancer